All In Biotech

Drug Trial Radar · NCT07298772

A Study of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Solid Tumors

A Phase Ib/II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-4375 Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

198

Planned (sponsor's estimate)

Start

Jan 7, 2026

Primary completion

Jan 2027

Study completion Jan 2028

Sponsor

Sponsor type
Industry
First posted
Dec 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, Phase Ib/II study to evaluate the safety, tolerability and efficacy of SHR-4375 injection in combination with other antitumor therapies in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • SHR-4375 InjectionDrug

    SHR-4375 injection in combination with other antitumor therapies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT).Time frame: 3 weeks.
  2. Recommended phase II dose (RP2D).Time frame: From screening period up to study completion, an average of 1 year.
  3. Adverse events (AEs).Time frame: From screening period up to study completion, an average of 1 year.
  4. Objective response rate (ORR).Time frame: From screening period up to study completion, an average of 1 year.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.